The role of serum-free light chain ratios in the prediction of poor prognosis in multiple myeloma patients: a systematic review and meta-analysis

References

• Bustoros M, Mouhieddine TH, Detappe A, et al. Established and novel prognostic biomarkers in multiple myeloma. Am Soc Clin Oncol Educ Book. 2017;37:548–560.
   PubMedGoogle Scholar
• Corre J, Cleynen A, Du Pont SR, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32(12):2636–2647.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37:62–65.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan;78(1):21–33.
   PubMed Web of Science ®Google Scholar
• Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(8):874–885.
   PubMed Web of Science ®Google Scholar
• Jain T, Sonbol MB, Firwana B, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25(2):239–247.
   PubMed Web of Science ®Google Scholar
• Avilés A, Neri N, Huerta-Guzmán J, et al. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Current Oncol. 2013;20(1):13–20.
   Web of Science ®Google Scholar
• Dejoie T, Corre J, Caillon H, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood. 2016;128(25):2941–2948.
   PubMed Web of Science ®Google Scholar
• Baker A, Braggio E, Jacobus S, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013;121(16):3147–3152.
   PubMed Web of Science ®Google Scholar
• Kriegova E, Fillerova R, Minarik J, et al. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021;11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Kumar S, Zhang L, Dispenzieri A, et al. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010;24(8):1498–1505.
   PubMed Web of Science ®Google Scholar
• Moustafa MA, Rajkumar SV, Dispenzieri A, et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015;29(10):2033–2038.
   PubMed Web of Science ®Google Scholar
• García de Veas Silva JL, Bermudo Guitarte C, Menéndez Valladares P, et al. Prognostic value of serum free light chains measurements in multiple myeloma patients. PLoS One. 2016;11(11):e0166841.
   PubMed Web of Science ®Google Scholar
• Du J, Lu J, Gao W, et al. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. Ann Hematol. 2020;99(8):1779–1791.
   PubMed Web of Science ®Google Scholar
• Özkurt ZN, Sucak GT, Akı ŞZ, et al. Early prognostic value of monitoring serum free light chain in patients with multiple myeloma undergoing autologous stem cell transplantation. Cancer Investig. 2017;35(3):195–201.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
   PubMed Web of Science ®Google Scholar
• Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14(1):1–5.
   PubMedGoogle Scholar
• Snozek CLH, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22(10):1933–1937.
   PubMed Web of Science ®Google Scholar
• Giarin MM, Giaccone L, Sorasio R, et al. Serum free light chain ratio, total κ/λ ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem. 2009;55(8):1510–1516.
   PubMed Web of Science ®Google Scholar
• Tacchetti P, Cavo M, Rocchi S, et al. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leuk Lymphoma. 2016;57(9):2058–2064.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–ee48.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27(4):941–946.
   PubMed Web of Science ®Google Scholar
• Singh G. Oligoclonal pattern/abnormal protein bands in post-treatment plasma cell myeloma patients: implications for protein electrophoresis and serum free light chain assay results. J Clin Med Res. 2017;9(8):671.
   PubMedGoogle Scholar
• Abdallah N, Kapoor P, Murray DL, et al. Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Adv. 2020;4(2):322–326.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Iwama K, Chihara D, Tsuda K, et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol. 2013;90(2):134–141.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Leung N, et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia. 2019;33(2):527–531.
   PubMed Web of Science ®Google Scholar
• Jekarl DW, Min C-K, Kwon A, et al. Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma. Ann Lab Med. 2013;33(4):248–254.
   PubMed Web of Science ®Google Scholar